NCT01448317 - Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Hypercholesterolemia

Interventions

DRUG

Alirocumab (Solution)

"Pharmaceutical form: solution~Route of administration: subcutaneous"

DRUG

Alirocumab (Lyophilized formulation)

"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"

DRUG

Placebo (Solution)

"Pharmaceutical form: solution~Route of administration: subcutaneous"

DRUG

Placebo (Lyophilized formulation)

"Pharmaceutical form: lyophilized formulation~Route of administration: Subcutaneous"

Trial Locations (1)

Sanofi-Aventis Administrative Office, Tokyo